Stoke Therapeutics, Inc.
NASDAQ:STOKBiotechnology
-$0.34 today
- Market cap
- $1.75B
- Beta
- 1.19
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$2.69
Volume 0.76M
Average 0.64M
STOK Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Stoke Therapeutics, Inc.NASDAQ: STOK
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin narrows to -857.6%
Operating margin was -857.6% in Q1 FY2026, down 927.7 pp from a year earlier. On a trailing-twelve-month basis it was -577.5%, down 597.5 pp year over year. Over 3 fiscal years it widened by 830.1 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 9 analysts of -652.1% for the fiscal year ending Dec 2026, down from -11.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -857.6%+3524.7 pp QoQ
- Last fiscal yearDec 2025
- -11.2%+266.1 pp YoY
- LTMMar 2026
- -577.5%-597.5 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -11.2%
- Year-over-year change
- +266.1pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -11.2% | +266.1pp |
| FY2024 | 2024-12-31 | -277.3% | +1029.9pp |
| FY2023 | 2023-12-31 | -1307.2% | -466.0pp |
| FY2022 | 2022-12-31 | -841.2% | — |
| FY2021 | 2021-12-31 | — | — |
Operating Margin vs competitors
How STOK compares with its peers on the latest reported figures
- STOK's LTM Mar 2026 operating margin of -577.5% is the 5th highest of the 6 companies compared; the peer median is -274.2%.
- Its year-over-year change of -597.5 pp is the lowest of 5, against a peer median of -92.3 pp.
- Over three fiscal years its change of +830.1 pp compares with a peer median of +281.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | -58.9% | -30.2 pp | +29.4 pp | |
| LTM Jun 2026 | -242.3% | +497.7 pp | +281.0 pp | |
| LTM Mar 2026 | -274.2% | -154.4 pp | +3955.2 pp | |
| LTM Mar 2026 | -345.5% | -170.5 pp | +1537.1 pp | |
| LTM Mar 2026 | -577.5% | -597.5 pp | +830.1 pp | |
| LTM Mar 2026 | -9396.6% | — | -15774.1 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding STOK) | -274.2% | -92.3 pp | +281.0 pp | |
Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 12.41M | 8.78M | 36.56M | 184.42M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 12.41M | 8.78M | 36.56M | 184.42M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 54.17M | 77.84M | 82.23M | 89.13M | 137.92M |
| Selling, General & Admin | 31.9M | 38.92M | 41.32M | 48.79M | 67.09M |
| Operating Expenses | 86.07M | 116.76M | 123.55M | 137.93M | 205.01M |
| Depreciation & Amortization | 974K | 1.55M | 2.47M | 2.18M | 1.77M |
| EBITDA | (84.83M) | (99.52M) | (102.23M) | (86.8M) | (5.12M) |
| EBITDA Margin | — | -802.3% | -1164.4% | -237.5% | -2.8% |
| Operating Income | (86.07M) | (104.36M) | (114.77M) | (101.37M) | (20.59M) |
| Operating Margin | — | -841.2% | -1307.2% | -277.3% | -11.2% |
| Interest Income | 120K | 3.12M | 9.91M | 12.64M | 13.77M |
| Interest Expense | 0 | 0 | 0 | 0 | 9K |
| Other Income / Expenses | 260K | 3.29M | 10.07M | 12.39M | 13.71M |
| Income Before Tax | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Pre-Tax Margin | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Net Margin | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| EPS (Basic) | (2.34) | (2.60) | (2.38) | (1.65) | (0.12) |
| EPS (Diluted) | (2.34) | (2.60) | (2.38) | (1.65) | (0.12) |
| Weighted Avg Shares | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
| Weighted Avg Shares (Diluted) | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
Stoke Therapeutics, Inc.
NASDAQ:STOK
Intrinsic Alpha fair value
Locked
Current Price
$26.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.